. Author manuscript; available in PMC: 2022 Jul 1.

Published in final edited form as: Clin Pharmacol Ther. 2021 Feb 16;110(1):179–188. doi: 10.1002/cpt.2161

Table 2:

Annual Estimated Prevalence of Gene-Drug Interactions

Medication	Annual prescription prevalence per 100,000 patients^a	95% CI lower	95% CI upper	Gene	Actionable phenotype^b	Annual estimated gene-drug interaction per 100,000 patients	95% CI lower	95% CI upper

Ondansetron	8,495	8,474	8,516	CYP2D6	UM	309	308	309
Oxycodone	6,647	6,627	6,667	CYP2D6	PM, IM, UM	1,137	1,134	1,141
Tramadol	2,506	2,490	2,522	CYP2D6	PM, IM, UM	438	435	441
Simvastatin	2,066	2,056	2,076	SLCO1B1	PF, DF	510	507	512
Codeine	1,091	1,083	1,099	CYP2D6	PM, IM, UM	189	188	191
Succinylcholine	1,020	1,011	1,029	CACNA1S	Positive^c	< 1	< 1	< 1
Succinylcholine	1,020	1,011	1,029	RYR1	Positive^c	1	1	1
Citalopram	1,016	1,008	1,023	CYP2C19	PM, RM, UM	339	336	341
Clopidogrel	879	872	886	CYP2C19	PM, IM	285	283	288
Warfarin	851	844	857	CYP2C9	PM, IM	277	275	279
Warfarin	851	844	857	VKORC1	Carrier^d	473	469	476
Escitalopram	677	671	682	CYP2C19	PM, RM, UM	227	225	229
Amitriptyline	674	668	681	CYP2C19	PM, RM, UM	222	220	225
Amitriptyline	674	668	681	CYP2D6	PM, IM, UM	117	116	118
Allopurinol	629	622	636	HLA-B58:01*	Positive^c	26	26	26

Only drugs with a prevalence ≥ 500 per 100,000 patients included. See Supplemental Table 3 for the other CPIC Level A drugs.

Actionable phenotype defined as a phenotype that would prompt a prescribing action according to CPIC guidance.

Positive is defined as harboring an actionable genetic variant.

Carrier is defined as a VKORC1 c-1639G>A heterozygote or homozygote. Abbreviations are as follows: UM=ultrarapid metabolizer, RM=rapid metabolizer, IM=intermediate metabolizer, PM=poor metabolizer, DF=decreased function, PF=poor function